Edward Morrow Atkinson III holds the role of EVP, Chief Technical Ops. Off. at VERTEX PHARMACEUTICALS INC / MA (VRTX). Atkinson's filing history also covers 89bio, Inc. (ETNB). Atkinson has reported 9 insider filings with the SEC since 2025. The most recent filing was in February 2026.
Every role Edward Morrow Atkinson III has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
VERTEX PHARMACEUTICALS INC / MA (VRTX)6 filings89bio, Inc. (ETNB)1 filingUpdated Aug 31, 2026
Edward Morrow Atkinson III is EVP, Chief Technical Ops. Off. of VERTEX PHARMACEUTICALS INC / MA (VRTX). 7 SEC Form 4 filings on record going back to 2025, most recently on 26 February 2026. Most recent open-market trade: sold $325K of VRTX on 26 February 2026. Lifetime open-market sales: $3.60M.
Every recent SEC Form 4 transaction Edward Morrow Atkinson III has reported, most recent first.
InsiderAlpha's records for Edward Morrow Atkinson III go back to 2025: 7 primary Form 4 filings, an average of 3.5 per year. 9 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Edward Morrow Atkinson III files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Edward Morrow Atkinson III is a corporate insider, tracked as EVP, Chief Technical Ops. Off. of VERTEX PHARMACEUTICALS INC / MA (VRTX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 26 February 2026, one of 7 filings going back to 2025.
Recorded transactions: 0 open-market purchases and 5 open-market sales ($3.60M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$VRTX VERTEX PHARMACEUTICALS INC / MA1.5K shares @ $483.75$740K
$VRTX VERTEX PHARMACEUTICALS INC / MA872 shares @ $468.41$408K